Our Pipeline

Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 81 clinical-stage projects, 31 of which are in phase 3 or have been submitted to regulatory authorities for approval. Some of these are new molecular entities while others are existing products with potential new indications, or different formulations. All of them are made possible by people who volunteer to participate in a clinical trial.

This page was updated on September 30, 2022

Phase 1

Phase 2

Phase 3

Registration

Phase 1

Phase 2

Phase 3

Resgistration

You can search or browse our R&D pipeline by therapeutic area, study phase, indication, or technology. Click on a candidate to see more details. We shared the latest updates to our pipeline at the Q3 Results Meeting, which took place on October 28, 2022. The brand names you see here are trademarks either owned by or licensed to Sanofi or associated companies. The safety and efficacy of these investigational agents have not been established.

Filters
Therapeutic Areas open
All phases open
All open
Search

projects of

Therapeutic Area

Phase

Name

Description

Indication

Downloads Available

Program Updates

We are no longer pursuing the following projects in our R&D programs.

Updated on September 30, 2022

Therapeutic Area

Phase

Name

Description

Additional Details

Related Links

Research & Development

Technology Platforms

Clinical Trials